Go Ad-Free
logoThe People's Perspective on Medicine

Is Drug Useless for Mild Dementia?

There are very few proven treatments for Alzheimer’s disease. One popular drug, Namenda, is approved for the treatment of moderate to severe Alzheimer’s dementia. Doctors often prescribe it to people with mild symptoms of the disease in the hope that they will maintain their ability to function. A new analysis of three studies shows that Namenda is no better than an inactive placebo pill for maintaining cognitive function and activities of daily living among people with mild Alzheimer’s. The researchers are not impressed with its benefit for people with moderate Alzheimer’s disease either. They call for better research demonstrating efficacy before doctors prescribe it for people with mild Alzheimer’s disease.
[Archives of Neurology, online, April 11, 2011]

Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
0- 0 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies..
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.